BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Bedaquiline Fumarate

Increased Mortality; QT Prologation

  • An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,2.5%) in one placebo-controlled trial. Only use SIRTURO when an effective treatment regimen cannot otherwise be provided.
  • QT prolongation can occur with SIRTURO. Use with drugs that prolong the QT interval may cause additive QT prolongation.

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Bedaquiline fumarate

Updated September 2016